Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology CRISPR drug development FDA Pharmaceuticals

	Profile	Recent Articles on Subject
1	Rick Berke STAT News Co-founder & executive editor. Longtime reporter. Boston, Massachusetts newsediting	STAT wins third Polk Award for Health Care’s Colossus series - 15 days ago STAT turns 8: A letter from the executive editor - over 1 year ago
2	Seth Joseph STAT News Data-driven optimist. Digital health strategist. Rhode Island digital healthstrategy	Opinion: STAT+: The travel industry offers hospitals a warning about MyChart - 15 days ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 18 days ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal - 3 months ago STAT+: Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: AstraZeneca says China has detained a senior executive - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Biotech is in a dark place - 19 days ago STAT+: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments - 3 months ago STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line - 4 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 6 months ago STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 6 months ago STAT+: On Andrew Left and the government’s fraud case - 7 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 11 months ago STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock - 11 months ago STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch - about 1 year ago STAT Virtual Event \| Cancer’s Breakthrough Engine - about 1 year ago
5	Brittany Trang STAT News Health care business reporter. PhD. Indie rock fan. health carebusiness reporting	STAT+: AI agents, bursting the AI drug hype bubble, and how health & medicine uses AI - 20 days ago STAT+: Why the crowded market for ambient AI medical scribes might be ripe for consolidation - 3 months ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Is Trump’s new order a reprieve for biotech? - 20 days ago STAT+: Merck drug for rare cardiovascular condition approved in U.S. - 11 months ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Denali Therapeutics spinout raises $200M as neuro company resets - about 2 months ago STAT+: ‘Significant talent shortage’ threatens the rise of radiopharmaceuticals - 3 months ago STAT+: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger - 3 months ago STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 6 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 6 months ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 9 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 12 months ago STAT Virtual Event \| 2024 JPM Recap, Live! - about 1 year ago
8	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Galapagos to split itself into two companies as part of turnaround plan - about 2 months ago STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study - 6 months ago STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 6 months ago STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more - 6 months ago STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried - 9 months ago STAT+: A scientific mystery highlights the blind spots in genomics databases - 12 months ago STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit - over 1 year ago
9	Tara Bannow STAT News Reporter @statnews. healthcarejournalism	STAT+: Latest updates to hospital price transparency rules aim to make the data more useful - 2 months ago STAT+: The dropped call that took down Centene’s Medicare Advantage star ratings - 4 months ago STAT+: For the behemoth UnitedHealth, a new threat to Medicare profits - 4 months ago STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers - 5 months ago STAT+: Humana cutting Medicare Advantage plans that cover 10% of members - 6 months ago
10	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	STAT stories you might have missed in 2024 - 2 months ago STAT+: Stump Pharmalot: An Ask Me Anything with Ed Silverman - about 1 year ago STAT stories you might have missed in 2023 - about 1 year ago STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D - over 1 year ago An Ask Me Anything with STAT’s Nicholas St. Fleur - over 1 year ago

Journalists covering STAT+